Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ARID1A Y551Lfs*72 ARID1A Q758Rfs*75 |
Therapy | Olaparib + Temozolomide |
Indication/Tumor Type | ovarian cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ARID1A Y551Lfs*72 ARID1A Q758Rfs*75 | ovarian cancer | sensitive | Olaparib + Temozolomide | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of Lynparza (olaparib) and Temodar (temozolomide) synergistically inhibited viability of an ovarian cancer cell line harboring ARID1A Y551Lfs*72 and Q758Rfs*75 in culture and inhibited tumor growth in a cell line xenograft model (PMID: 37306706). | 37306706 |
PubMed Id | Reference Title | Details |
---|---|---|
(37306706) | Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors. | Full reference... |